Clene Nanomedicine – Neurodegenerative Diseases

Rob Etherington, CEO at Clene Nanomedicine discusses the company’s lead drug candidate CNM-Au8, a catalytically active gold nanotherapeutic that drives critical cellular energy producing reactions in the brain that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. The company recently announced completion of a Phase 2 study in amyotrophic lateral sclerosis (ALS). CNM-Au8 is also being evaluated in a Phase 3 trial for the treatment of ALS, and in two Phase 2 open-label biomarker clinical trials in the treatment of Parkinson’s disease and multiple sclerosis. 

Mr. Rob Etherington, President and Chief Executive Officer at  Clene Nanomedicine. Clene’s lead drug candidate is CNM-Au8, a catalytically active gold nanotherapeutic that drives critical cellular energy producing reactions in the brain that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. The company recently announced completion of a Phase 2 study in amyotrophic lateral sclerosis (ALS). CNM-Au8 is also being evaluated in a Phase 3 trial for the treatment of ALS, and in two Phase 2 open-label biomarker clinical trials in the treatment of Parkinson’s disease and multiple sclerosis. Mr. Etherington brings nearly 30 years of sales, marketing and leadership experience in the pharmaceutical industry to Clene. Prior, he worked for Actelion Pharmaceuticals, which was the largest pharmaceutical company based in the EU until Johnson & Johnson Pharmaceuticals acquired the company in 2017. He initially joined Actelion as founding Director of Marketing in 2000, the same year the company went public, and went on to hold various roles of increasing responsibility. Mr. Etherington served as the first U.S. commercial employee, leading U.S. commercial operations and serving a Cahir of the U.S, Commercial Strategic team where he was responsible for five marketed drugs. Prior to Action, Mr. Etherington began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a team Leader position that oversaw the drug Lipitor.